Intrinsic value of Balchem - BCPC

Previous Close

$74.85

  Intrinsic Value

$36.49

stock screener

  Rating & Target

str. sell

-51%

Previous close

$74.85

 
Intrinsic value

$36.49

 
Up/down potential

-51%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BCPC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of Balchem (BCPC) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.18
  8.60
  8.24
  7.92
  7.62
  7.36
  7.13
  6.91
  6.72
  6.55
  6.39
  6.26
  6.13
  6.02
  5.92
  5.82
  5.74
  5.67
  5.60
  5.54
  5.49
  5.44
  5.39
  5.35
  5.32
  5.29
  5.26
  5.23
  5.21
  5.19
  5.17
Revenue, $m
  553
  601
  650
  702
  755
  811
  868
  928
  991
  1,056
  1,123
  1,193
  1,267
  1,343
  1,422
  1,505
  1,591
  1,682
  1,776
  1,874
  1,977
  2,085
  2,197
  2,315
  2,438
  2,567
  2,702
  2,843
  2,991
  3,146
  3,309
Variable operating expenses, $m
 
  496
  533
  572
  612
  654
  697
  743
  789
  838
  889
  898
  953
  1,010
  1,070
  1,132
  1,197
  1,265
  1,336
  1,410
  1,488
  1,568
  1,653
  1,742
  1,834
  1,931
  2,033
  2,139
  2,251
  2,367
  2,490
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  462
  496
  533
  572
  612
  654
  697
  743
  789
  838
  889
  898
  953
  1,010
  1,070
  1,132
  1,197
  1,265
  1,336
  1,410
  1,488
  1,568
  1,653
  1,742
  1,834
  1,931
  2,033
  2,139
  2,251
  2,367
  2,490
Operating income, $m
  91
  105
  117
  130
  143
  157
  171
  186
  201
  217
  234
  295
  314
  332
  352
  373
  394
  416
  440
  464
  489
  516
  544
  573
  603
  635
  669
  704
  740
  779
  819
EBITDA, $m
  137
  170
  184
  198
  213
  229
  246
  263
  280
  298
  318
  337
  358
  380
  402
  426
  450
  475
  502
  530
  559
  589
  621
  654
  689
  726
  764
  804
  846
  890
  936
Interest expense (income), $m
  7
  9
  10
  11
  12
  14
  15
  16
  18
  19
  21
  23
  24
  26
  28
  30
  32
  34
  37
  39
  41
  44
  47
  49
  52
  55
  59
  62
  66
  69
  73
Earnings before tax, $m
  83
  96
  107
  119
  131
  143
  156
  169
  183
  198
  213
  273
  289
  306
  324
  342
  362
  382
  403
  425
  448
  472
  497
  524
  551
  580
  610
  642
  675
  710
  746
Tax expense, $m
  27
  26
  29
  32
  35
  39
  42
  46
  50
  53
  58
  74
  78
  83
  87
  92
  98
  103
  109
  115
  121
  127
  134
  141
  149
  157
  165
  173
  182
  192
  201
Net income, $m
  56
  70
  78
  87
  95
  104
  114
  124
  134
  144
  155
  199
  211
  223
  236
  250
  264
  279
  294
  310
  327
  345
  363
  382
  402
  423
  445
  469
  493
  518
  545

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  39
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  949
  988
  1,069
  1,154
  1,242
  1,333
  1,428
  1,527
  1,630
  1,736
  1,847
  1,963
  2,083
  2,209
  2,339
  2,475
  2,617
  2,766
  2,921
  3,083
  3,252
  3,428
  3,613
  3,807
  4,009
  4,221
  4,443
  4,676
  4,919
  5,175
  5,442
Adjusted assets (=assets-cash), $m
  910
  988
  1,069
  1,154
  1,242
  1,333
  1,428
  1,527
  1,630
  1,736
  1,847
  1,963
  2,083
  2,209
  2,339
  2,475
  2,617
  2,766
  2,921
  3,083
  3,252
  3,428
  3,613
  3,807
  4,009
  4,221
  4,443
  4,676
  4,919
  5,175
  5,442
Revenue / Adjusted assets
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
  0.608
Average production assets, $m
  304
  330
  357
  385
  414
  445
  477
  510
  544
  580
  617
  655
  695
  737
  781
  826
  874
  923
  975
  1,029
  1,085
  1,144
  1,206
  1,271
  1,338
  1,409
  1,483
  1,561
  1,642
  1,727
  1,817
Working capital, $m
  87
  90
  98
  105
  113
  122
  130
  139
  149
  158
  168
  179
  190
  201
  213
  226
  239
  252
  266
  281
  297
  313
  330
  347
  366
  385
  405
  426
  449
  472
  496
Total debt, $m
  280
  279
  314
  350
  388
  428
  469
  512
  556
  602
  650
  700
  752
  806
  863
  921
  983
  1,047
  1,114
  1,184
  1,257
  1,333
  1,413
  1,497
  1,584
  1,676
  1,772
  1,872
  1,977
  2,087
  2,203
Total liabilities, $m
  428
  427
  462
  498
  536
  576
  617
  660
  704
  750
  798
  848
  900
  954
  1,011
  1,069
  1,131
  1,195
  1,262
  1,332
  1,405
  1,481
  1,561
  1,645
  1,732
  1,824
  1,920
  2,020
  2,125
  2,235
  2,351
Total equity, $m
  521
  561
  607
  655
  705
  757
  811
  867
  926
  986
  1,049
  1,115
  1,183
  1,254
  1,329
  1,406
  1,487
  1,571
  1,659
  1,751
  1,847
  1,947
  2,052
  2,162
  2,277
  2,398
  2,524
  2,656
  2,794
  2,939
  3,091
Total liabilities and equity, $m
  949
  988
  1,069
  1,153
  1,241
  1,333
  1,428
  1,527
  1,630
  1,736
  1,847
  1,963
  2,083
  2,208
  2,340
  2,475
  2,618
  2,766
  2,921
  3,083
  3,252
  3,428
  3,613
  3,807
  4,009
  4,222
  4,444
  4,676
  4,919
  5,174
  5,442
Debt-to-equity ratio
  0.537
  0.500
  0.520
  0.530
  0.550
  0.570
  0.580
  0.590
  0.600
  0.610
  0.620
  0.630
  0.640
  0.640
  0.650
  0.660
  0.660
  0.670
  0.670
  0.680
  0.680
  0.680
  0.690
  0.690
  0.700
  0.700
  0.700
  0.700
  0.710
  0.710
  0.710
Adjusted equity ratio
  0.530
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568
  0.568

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  56
  70
  78
  87
  95
  104
  114
  124
  134
  144
  155
  199
  211
  223
  236
  250
  264
  279
  294
  310
  327
  345
  363
  382
  402
  423
  445
  469
  493
  518
  545
Depreciation, amort., depletion, $m
  46
  65
  67
  69
  71
  73
  75
  77
  79
  81
  84
  42
  45
  47
  50
  53
  56
  59
  62
  66
  70
  73
  77
  81
  86
  90
  95
  100
  105
  111
  116
Funds from operations, $m
  113
  135
  145
  155
  166
  177
  188
  200
  213
  226
  239
  241
  256
  271
  286
  303
  320
  338
  357
  376
  397
  418
  440
  464
  488
  514
  540
  569
  598
  629
  661
Change in working capital, $m
  5
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  11
  12
  12
  13
  14
  14
  15
  15
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
Cash from operations, $m
  108
  128
  138
  148
  158
  169
  180
  191
  203
  216
  229
  231
  245
  259
  275
  290
  307
  324
  343
  361
  381
  402
  423
  446
  470
  494
  520
  547
  576
  606
  637
Maintenance CAPEX, $m
  0
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -47
  -50
  -53
  -56
  -59
  -62
  -66
  -70
  -73
  -77
  -81
  -86
  -90
  -95
  -100
  -105
  -111
New CAPEX, $m
  -24
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -34
  -36
  -37
  -39
  -40
  -42
  -44
  -45
  -47
  -50
  -52
  -54
  -56
  -59
  -62
  -65
  -68
  -71
  -74
  -78
  -81
  -85
  -89
Cash from investing activities, $m
  -134
  -45
  -48
  -51
  -54
  -58
  -61
  -64
  -67
  -71
  -74
  -79
  -82
  -87
  -91
  -95
  -100
  -106
  -111
  -116
  -122
  -129
  -135
  -142
  -149
  -157
  -164
  -173
  -181
  -190
  -200
Free cash flow, $m
  -26
  82
  89
  96
  104
  112
  120
  128
  136
  145
  155
  152
  162
  173
  184
  195
  207
  219
  232
  245
  259
  273
  288
  304
  321
  338
  356
  375
  394
  415
  437
Issuance/(repayment) of debt, $m
  -17
  34
  35
  37
  38
  39
  41
  43
  44
  46
  48
  50
  52
  54
  56
  59
  61
  64
  67
  70
  73
  76
  80
  84
  87
  92
  96
  100
  105
  110
  116
Issuance/(repurchase) of shares, $m
  6
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -8
  34
  35
  37
  38
  39
  41
  43
  44
  46
  48
  50
  52
  54
  56
  59
  61
  64
  67
  70
  73
  76
  80
  84
  87
  92
  96
  100
  105
  110
  116
Total cash flow (excl. dividends), $m
  -35
  116
  125
  133
  142
  151
  161
  170
  181
  191
  203
  202
  214
  227
  240
  254
  268
  283
  299
  315
  332
  350
  368
  388
  408
  429
  452
  475
  500
  525
  552
Retained Cash Flow (-), $m
  -57
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -61
  -63
  -66
  -68
  -71
  -74
  -77
  -81
  -84
  -88
  -92
  -96
  -100
  -105
  -110
  -115
  -120
  -126
  -132
  -138
  -145
  -152
Prev. year cash balance distribution, $m
 
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  76
  78
  85
  92
  99
  107
  114
  122
  131
  140
  137
  146
  156
  166
  176
  187
  199
  211
  223
  236
  249
  263
  278
  293
  309
  326
  343
  361
  380
  400
Discount rate, %
 
  5.20
  5.46
  5.73
  6.02
  6.32
  6.64
  6.97
  7.32
  7.68
  8.07
  8.47
  8.89
  9.34
  9.81
  10.30
  10.81
  11.35
  11.92
  12.51
  13.14
  13.80
  14.49
  15.21
  15.97
  16.77
  17.61
  18.49
  19.41
  20.38
  21.40
PV of cash for distribution, $m
 
  72
  70
  72
  73
  73
  73
  71
  70
  67
  64
  56
  53
  49
  45
  41
  36
  32
  28
  24
  20
  17
  13
  11
  8
  6
  5
  4
  3
  2
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Balchem Corporation is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization and industrial markets. The Company operates in four segments: Human Nutrition & Health, Animal Nutrition & Health, Specialty Products and Industrial Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry, providing solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems and cereal systems. The Animal Nutrition & Health segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment sells ethylene oxide as a sterilant gas primarily for use in the healthcare industry. The Industrial Products segment includes the manufacture and sale of methylamines.

FINANCIAL RATIOS  of  Balchem (BCPC)

Valuation Ratios
P/E Ratio 42.5
Price to Sales 4.3
Price to Book 4.6
Price to Tangible Book
Price to Cash Flow 22
Price to Free Cash Flow 28.3
Growth Rates
Sales Growth Rate 0.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -42.9%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 47%
Total Debt to Equity 53.7%
Interest Coverage 13
Management Effectiveness
Return On Assets 6.6%
Ret/ On Assets - 3 Yr. Avg. 7.7%
Return On Total Capital 7.2%
Ret/ On T. Cap. - 3 Yr. Avg. 8.4%
Return On Equity 11.4%
Return On Equity - 3 Yr. Avg. 13.4%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 32.7%
Gross Margin - 3 Yr. Avg. 29.9%
EBITDA Margin 24.6%
EBITDA Margin - 3 Yr. Avg. 23.2%
Operating Margin 16.5%
Oper. Margin - 3 Yr. Avg. 16.2%
Pre-Tax Margin 15%
Pre-Tax Margin - 3 Yr. Avg. 15%
Net Profit Margin 10.1%
Net Profit Margin - 3 Yr. Avg. 10.3%
Effective Tax Rate 32.5%
Eff/ Tax Rate - 3 Yr. Avg. 31.6%
Payout Ratio 19.6%

BCPC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCPC stock intrinsic value calculation we used $553 million for the last fiscal year's total revenue generated by Balchem. The default revenue input number comes from 2016 income statement of Balchem. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCPC stock valuation model: a) initial revenue growth rate of 8.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.2%, whose default value for BCPC is calculated based on our internal credit rating of Balchem, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Balchem.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCPC stock the variable cost ratio is equal to 83.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BCPC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Balchem.

Corporate tax rate of 27% is the nominal tax rate for Balchem. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCPC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCPC are equal to 54.9%.

Life of production assets of 15.6 years is the average useful life of capital assets used in Balchem operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCPC is equal to 15%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $521 million for Balchem - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 31.762 million for Balchem is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Balchem at the current share price and the inputted number of shares is $2.4 billion.

RELATED COMPANIES Price Int.Val. Rating
SXT Sensient Techn 72.30 26.82  str.sell
IPHS Innophos Holdi 43.66 20.43  str.sell
MMM 3M 232.18 160.70  sell
ACET Aceto 7.33 34.88  str.buy
EMN Eastman Chemic 101.09 72.57  sell
BUFF Blue Buffalo P 34.80 57.75  str.buy

COMPANY NEWS

▶ ETFs with exposure to Balchem Corp. : December 29, 2017   [Dec-29-17 11:33AM  Capital Cube]
▶ Balchem Corporation Announces Dividend   [Dec-15-17 09:00AM  GlobeNewswire]
▶ ETFs with exposure to Balchem Corp. : December 7, 2017   [Dec-07-17 01:00PM  Capital Cube]
▶ Industrial Sales Boost Balchem Corporation's Bottom Line   [Nov-14-17 07:31AM  Motley Fool]
▶ Blachem posts 3Q profit   [07:29AM  Associated Press]
▶ ETFs with exposure to Balchem Corp. : October 26, 2017   [Oct-26-17 10:20AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : October 10, 2017   [Oct-10-17 11:02AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : September 26, 2017   [Sep-26-17 10:43AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : September 12, 2017   [Sep-11-17 09:32PM  Capital Cube]
▶ Blachem posts 2Q profit   [Aug-04-17 10:21PM  Associated Press]
▶ ETFs with exposure to Balchem Corp. : July 4, 2017   [Jul-04-17 02:38PM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : June 22, 2017   [Jun-22-17 03:25PM  Capital Cube]
▶ Balchem Reports Record Earnings in First Quarter   [May-09-17 02:13PM  Motley Fool]
▶ Blachem posts 1Q profit   [10:11AM  Associated Press]
▶ Balchem Corp. Value Analysis (NASDAQ:BCPC) : May 3, 2017   [May-03-17 04:35PM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : April 19, 2017   [Apr-19-17 02:12PM  Capital Cube]
▶ Health Products Drive Balchem Corporation's Growth   [Mar-01-17 03:43PM  Motley Fool]
▶ Blachem posts 4Q profit   [08:23AM  Associated Press]
▶ 3 Stocks That Turned $10,000 Into at Least $3.68 Million   [Feb-13-17 12:03PM  Motley Fool]
▶ [$$] LBO Focus: Private Equity Whets Appetite for Ingredients Deals   [Feb-01-17 09:24AM  at The Wall Street Journal]
▶ Balchem Corporation Announces Dividend   [11:29AM  GlobeNewswire]
▶ Is Finisar Corporation (FNSR) A Good Stock To Buy?   [Nov-30-16 03:40PM  at Insider Monkey]
▶ Do Hedge Funds Love KBR, Inc. (KBR)?   [Nov-28-16 08:38AM  at Insider Monkey]
▶ Balchem Corporation Sees Steady Health and Nutrition Growth   [Nov-08-16 11:06AM  at Motley Fool]
Financial statements of BCPC
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.